SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Oct 4, 2018

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Oct. 4, 2018 · CIK: 0000894158 · Accession: 0001144204-18-052523

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-227400

Date

October 4, 2018

Author

Steven A. Shallcross

Form

CORRESP

Company

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

VIA EDGAR Division of Corporation Finance Attention: Christine Westbrook Re: Synthetic Biologics, Inc. Registration Statement on Form S-1 File No. 333-227400

Dear Ms. Westbrook:

Synthetic Biologics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1, as amended (File No. 333-227400), be accelerated by the U.S. Securities and Exchange Commission to Tuesday, October 9, 2018 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.

The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Very truly yours,
Synthetic Biologics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

 Synthetic Biologics, Inc.

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

October 4, 2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Christine Westbrook

Re: 	Synthetic Biologics,
Inc.

Registration Statement
on Form S-1

File No. 333-227400

Dear Ms. Westbrook:

Synthetic Biologics,
Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on
Form S-1, as amended (File No. 333-227400), be accelerated by the U.S. Securities and Exchange Commission to Tuesday,
October 9, 2018 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.

The Company hereby
authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration.
Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have
concerning this request, and please notify either of them when this request for acceleration has been granted.

    Very truly yours,

    Synthetic Biologics, Inc.

    By:
    /s/ Steven A. Shallcross

    Name:
    Steven A. Shallcross

    Title:

    Interim Chief Executive Officer and Chief Financial Officer

SecProbe.io